Currently out of the existing stock ratings of Oren Livnat, 18 are a HOLD (7.66%), 217 are a BUY (92.34%).

Oren Livnat

Work Performance Price Targets & Ratings Chart

Analyst Oren Livnat, carries an average stock price target met ratio of 47.74% that have a potential upside of 51.42% achieved within 268 days. Previously, Oren Livnat worked at HC WAINWRIGHT.

Oren Livnat’s has documented 427 price targets and ratings displayed on 26 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on PCRX, Pacira Pharmaceuticals at 08-Apr-2025.

Wall Street Analyst Oren Livnat

Analyst best performing recommendations are on MNLO (MENLO THERAPEUTICS).
The best stock recommendation documented was for VYNE (VYNE THERAPEUTICS) at 5/12/2020. The price target of $180 was fulfilled within 16 days with a profit of $49.68 (38.12%) receiving and performance score of 23.83.

Average potential price target upside

of $59.76 (66.15%) on VYNE (VYNE THERAPEUTICS).
of $55.1 (71.36%) on VRCA (VERRICA PHARMACEUTICALS).
of $25.32 (127.16%) on TARS (TARSUS PHARMACEUTICALS ).

PCRX Pacira Pharmaceuticals AERI Aerie Pharmaceuticals AGRX Agile Thrpe ATRS Antares Pharma BDSI BioDelivery Sciences International COLL Collegium Pharmaceutical KMPH KemPharm SCYX Scynexis NOVN Novan VRCA Verrica Pharmaceuticals STSA Satsuma Pharmaceuticals XERS Xeris Pharmaceuticals ANIP ANI Pharmaceuticals AVDL Avadel Pharmaceuticals PLC CARA Cara Therapeutic JAZZ Jazz Pharmaceuticals PLC MNKD MannKind Corp TARS Tarsus Pharmaceuticals LPCN Lipocine MNLO Menlo Therapeutics OTIC Otonomy VYNE Vyne Therapeutics ZYNE Zynerba Pharmaceuticals ACST Acasti Pharma TRVI Trevi Therapeutics CORI Corium International

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Douglas Tsao (HC WAINWRIGHT)